Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Beta-1A in Moderate to Severe COVID-19
NCT04350671Phase 4
Key facts
- Status
- Unknown
- Start
- Apr 2020
- Primary completion
- Apr 2020
- Countries
- 1
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Modality
- Cytokines & Interferons
- Drugs
- interferon beta-1a
- Conditions
- coronavirus disease 2019 (COVID-19)
01
Overview
Phase 4, randomised, double-blind trial of interferon beta-1a in coronavirus disease 2019 (COVID-19), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Time to clinical improvement at 14 days. Status: unknown.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients aged 50 and older with confirmed moderate to severe COVID-19 (SpO2 ≤ 88%, RR ≥ 24) and acute symptom onset (≤ 10 days).
04
Endpoints
Primary
Time to clinical improvement
Beyond the preview
Go deeper on NCT04350671.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04350671.